Long QT syndrome is a well-known cardiac disorder of myocardial repolarisation. Te syndrome is primary characterized in ECG registration by prolongation of the QT interval from less than 500 ms to higher values up to 660 ms. The Long QT syndrome is associated with potentially life-threatening cardiac arrhythmias as ventricular tachycardia (Torsade de pointes) as well as ventricular fibrillation, and might lead to syncope as well as sudden cardiac death (1). Good results have been achieved by treating patient at risk with beta-blockers and ICD devices. It is therefore important to diagnose the condition and risks stratify patients with Long QT syndrome, as the disease is treatable.
Prolonged QT duration might also be induced by the intake of numerous pharmaceutical substances, as well as with electrolyte disturbances, which is also increasing the risk of life-threatening cardiac arrhythmias. More than 30 pharmaceutical substances sold in Norway have been associated with QT prolongation. A recent study performed in a selected American referral hospital (Mayo Clinic) describe that the prognosis of patients with acquired QT prolongation, might be less favourable than for other patients (Haugaa & Ackerman). Our study shall investigate if this can be confirmed in a community hospital with fewer inherited cases. If this can be confirmed doctors should increase their awareness on treating QT prolongation.